Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

18.52 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 18.52
Bid (Size) 17.90 (100)
Ask (Size) 22.00 (100)
Prev. Close 18.52
Today's Range 18.52 - 18.52
52wk Range 9.030 - 20.17
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum ↗
Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate. 
Via Chartmill
News headline image
Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss ↗
Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data. 
Via Chartmill

Performance

YTD
+25.3%
+25.3%
1 Month
+0.7%
+0.7%
3 Month
+31.8%
+31.8%
6 Month
+56.7%
+56.7%
1 Year
+24.2%
+24.2%

More News

Read More
News headline image
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
5 Analysts Have This To Say About Zymeworks ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
Via Benzinga
News headline image
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit ↗
Via Benzinga
News headline image
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update ↗
Via Stocktwits
News headline image
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
From Zymeworks Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge ↗
Via Stocktwits
News headline image
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 18.52
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 11/14/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.